ORKA-002 PK simulation
Indication: Moderate to severe plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa
Interactive bimekizumab (BIMZELX) pharmacokinetic simulator based on FDA label population PK, with plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa regimens.
Drug Overview
Clinical Context
- Molecular Target
- IL-17A and IL-17F
- Drug Class
- IL-17A/IL-17F monoclonal antibody
- Therapeutic Area
- Immunology/Dermatology
- Indication
- Moderate to severe plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa
- Route of Administration
- Subcutaneous
Model Information
- Model Type
- 1-compartment SC PopPK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
Pharmacokinetic Parameters
PK Parameters
| Parameter | Value |
|---|---|
| F | 0.7 |
Additional Parameters
| Parameter | Value |
|---|---|
| V L | 7.84 |
| KA per day | 1.043 |
| CL L per day | 0.2359 |
| half life days | 23 |
| hs v multiplier | 1.18 |
| hs cl multiplier | 1.31 |
| weight exponent v | 1 |
| weight exponent cl | 1.11 |
| reference weight kg | 87 |
| single dose tmax days | 3.5 |
| single dose cmax ug per ml | 25.7 |
Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.
About This Simulator
This interactive pharmacokinetic simulator for ORKA-002 allows you to explore concentration-time profiles under different dosing scenarios. The underlying 1-compartment SC PopPK model characterizes the pharmacokinetics of this il-17a/il-17f monoclonal antibody following subcutaneous administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the ORKA-002 PK simulator?
This is a free, interactive pharmacokinetic simulator for ORKA-002 used in Moderate to severe plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does ORKA-002 belong to?
ORKA-002 is classified as a IL-17A/IL-17F monoclonal antibody that targets IL-17A and IL-17F. It is used in the Immunology/Dermatology therapeutic area.
What route of administration does this model simulate?
This simulator models Subcutaneous administration of ORKA-002. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a 1-compartment SC PopPK model. Population PK models account for interindividual variability and covariate effects on drug exposure.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Ready to Simulate?
Launch the ORKA-002 simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community